CVT begins second regadenoson study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics has initiated a second cardiac perfusion imaging trial of its pharmacologic stress agent regadenoson (CVT-3146), the firm announces April 26. CVT and partner Fujisawa plan to submit an NDA "as quickly as possible." CVT is highlighting a potential safety benefit via regadenoson's selectivity for the A2A-adenosine receptor, responsible for coronary vasodilation. The first Phase III trial started in October 2003...
You may also be interested in...
CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006
CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.